Wedbush analyst Seth Basham downgrades Bed Bath & Beyond (NASDAQ:BBBY) from Neutral to Underperform and announces $5 price target.
ImmunityBio Announces Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis
https://clinicaltrials.gov/study/NCT06040918Study OverviewBrief Summary:This is phase 1 single cohort study evaluating the effects of N-803 administration on mononuclear cells (MNC) collected from healthy donors
